1. Home
  2. NFE vs IFRX Comparison

NFE vs IFRX Comparison

Compare NFE & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Fortress Energy Inc.

NFE

New Fortress Energy Inc.

HOLD

Current Price

$6.32

Market Cap

324.4M

Sector

Utilities

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.93

Market Cap

303.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NFE
IFRX
Founded
2014
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.4M
303.4M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
NFE
IFRX
Price
$6.32
$1.93
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$5.50
★ $6.25
AVG Volume (30 Days)
★ 2.4M
577.8K
Earning Date
04-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $1,504,037,000.00
N/A
Revenue This Year
$110.34
N/A
Revenue Next Year
$3.54
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.23
$0.80
52 Week High
$16.90
$2.95

Technical Indicators

Market Signals
Indicator
NFE
IFRX
Relative Strength Index (RSI) 53.51 42.95
Support Level $0.61 $1.58
Resistance Level $16.90 $2.38
Average True Range (ATR) 1.14 0.11
MACD 0.03 -0.02
Stochastic Oscillator 34.45 2.40

Price Performance

Historical Comparison
NFE
IFRX

About NFE New Fortress Energy Inc.

New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: